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Abstract
Background: The role of psycosocial factors in the disease progression of chronic hepatitis C (CHC) patients
remains unclear. The aim of the present study was to prospectively evaluate the prognostic value of behavioral
patterns and the quality of life (QOL) of patients with CHC.
Methods: Two hundred and forty Japanese CHC patients (mean age 62.4 years) were assessed for behavioral
patterns (Stress Inventory), QOL (Functional Assessment of Chronic Illness Therapy-Spiritual), and known prognostic
factors at baseline then followed for a maximum of 8 years for disease progression, defined as either the first
diagnosis of hepatocellular carcinoma (HCC) or hepatitis-related death.
Results: Forty-nine events occurred during the study period (46 newly diagnosed HCC cases, three hepatitis-related
deaths). In a Cox proportional hazard model including known prognostic factors and treatment-related factors as
time-dependent variables, behavioral patterns associated with inhibition of emotional needs (hazard ratio (HR): 1.35;
95 % confidence interval (CI): 1.02–1.77; p = 0.036) and QOL, representing emotional wellbeing (HR 0.60; 95 % CI
0.37–0.98; p = 0.041), were each associated with the risk of disease progression.
Conclusion: Psychosocial factors such as behavioral patterns relevant to the inhibition of emotional needs and
emotional wellbeing independently affect the clinical course of patients with CHC.
Keywords: Chronic hepatitis, Psychosocial stress, Quality of life, Emotion, Hepatocellular carcinoma, Prognosis
Background
Chronic hepatitis C (CHC) is a major public health
problem. According to recent estimates, more than 130-
150 million people around the world have been infected
with the hepatitis C virus (HCV). Of those with chronic
HCV infection, the risk of cirrhosis is 15–30 % within
20 years. A significant number of those who are chronic-
ally infected will deverop hepatocellular carcinoma (HCC)
which is a major life-threatening complication. Approxi-
mately 700,000 people die each year from hepatitis C-
related liver diseases.[1]. Extant research has found that
HCV genotype 1b [2], older age, male sex, elevation in the
serum bilirubin, decreased platelet count, and alcohol in-
take [3] contribute to the development of HCC by patients
with CHC; however, the role of psychosocial factors in the
initiation and progression of HCC remains unclear.
In a series of animal experiments, we demonstrated a
relationship between stress and liver diseases [4–6]. For
example, electric foot-shock stress exacerbated liver in-
jury in a hepatitis model using α-galactosylceramide [4].
In a Fas-induced liver injury model, we showed that the
hepatic sympathetic nerve protects against Fas-induced
liver injury by maintaining interleukin-6 levels in the
liver [5]. Furthermore, in a study using a selective hep-
atic vagotomy technique, the hepatic vagus nerve atten-
uated Fas-induced hepatocyte apoptosis through the α7
nicotinic acetylcholine receptor [6]. These findings
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collectively suggest that the liver reciprocally interacts
with the brain via the endocrine and autonomic nerve
systems. In accordance with these findings obtained
from animal studies, some decades-old clinical literature
suggests that psychosocial stress may affect the initiation
and clinical course of liver diseases. For example,
Fukudo et al. found that the severity of psychosocial
stress was significantly correlated with the exaggeration
of inflammatory and fibrosing changes in patients with
alcoholic hepatitis [7]. Moreover, we previously reported
that the “type-I behavior pattern” was associated with
CHC severity after adjusting for age, sex, education level,
smoking, drinking, and duration of illness [8]. Type-I be-
havior, originally proposed by Grossarth-Maticek as a
cancer-prone behavioral pattern [9, 10], is characterized
by marked repression of emotions and altruistic behavior
in interpersonal relationships [9]. Nonetheless, as the
observed association between type-I behavior and CHC
severity was based on retrospective data, the causal rela-
tionship between such psychosocial factors and the clin-
ical course of CHC remains undetermined.
Recently, research has examined quality of life (QOL)
in terms of its ability to predict the clinical course of
chronic diseases, including various types of cancer
[11, 12] (e.g. of the lung [13, 14], esophagus [15],
head and neck [16], colon [17], and ovary [18]), in
addition to its role as an outcome of chronic diseases
(e.g. the negative effect of CHC on patients’ QOL [19]).
Further, QOL may predict the clinical course of patients
with HCC [20–22]. Nonetheless, there is presently no pro-
spective data on QOL as a predictor of the course of
CHC. The present study therefore aimed to evaluate the
prognostic values of psychosocial factors in a group of pa-
tients with CHC, based on 8 years of prospective data that
incorporated known prognostic factors.
Methods
Enrollment of subjects
The study protocol was approved by the Ethics
Committee of the Faculty of Medical Science, Kyushu
University. Patients with CHC who were regularly visiting
the Steel Memorial Yawata Hospital in Kitakyushu city,
Japan during the period from September to December
2003 were invited to participate. Criteria for recruitment
were 1) age under 80 years; 2) no decompensated cirrhosis
symptoms, such as intractable ascites, variceal bleeding, or
encephalopathy; 3) no history of malignant diseases
including HCC; 4) no medical conditions preventing
completion of a self-administered questionnaire without
assistance; and 5) no co-infection with hepatitis B virus.
Patients who had succeeded in eliminating hepatitis C
virus with interferon treatment and continued visiting the
hospital for follow-up were also included.
The attending hepatologist informed a series of eligible
patients of the study’s details and asked the patients to
participate. Participating patients signed a consent form,
completed a set of questionnaires at home, and mailed
them to a central office (Faculty of Psychosomatic
Medicine, Kyushu University Graduate School of Medical
Sciences). A gift certificate worth around 10 USD was
then sent to the participants as gratitude.
Psychosocial assessment
The stress inventory
The Stress Inventory (SI) is a 45-item, self-report ques-
tionnaire developed by Nagano et al. to assess behavioral
patterns that hypothetically relate to the development of
chronic diseases such as cancer and cardiovascular
disease [8, 23, 24]. The SI consists of 12 scales, four of
which were designed to measure elements of type-I be-
havior, which is characterized by marked inhibition of
emotional needs [25]: “Low sense of control,” diminished
sense of control over stressful situations, leading to
hardship, despair, or anger; “object dependence of loss,”
having an important person in one’s life who causes per-
sistent hopelessness and depression; “unfulfilled need for
acceptance,” chronically having an unfulfilled need for
acceptance by others; and “altruism,” an altruistic ten-
dency, accompanied by stress, in interpersonal and social
relationships. Responses used a 6-point scale (1 = yes or
almost always, 6 = no or rarely); item scores were
averaged to give the scale score; higher scale scores thus
represented a stronger type-I tendency. The “type-I score”
was also calculated by averaging the four scale scores [8].
The Functional Assessment of Chronic Illness
Therapy-Spiritual (FACIT-Sp)
The FACIT-Sp is a 41-item, self-report questionnaire de-
veloped by Cella et al. [26] to assess multiple domains of
QOL, including spirituality, and intended for use in re-
search examining people with chronic and/or life-
threatening illnesses. It consists of five scales that corres-
pond to five domains of QOL: “physical wellbeing,”
comprising reports of physical symptoms; “functional
wellbeing,” assessing the degree to which a respondent is
able to participate in and enjoy normal daily activities;
“social/familial wellbeing,” representing social support and
communication; “emotional wellbeing,” measuring mood
and emotional response to illness; and “spiritual wellbeing,”
representing a sense of meaning in one’s life, inner har-
mony, peacefulness, and a sense of comfort and strength in
one’s spiritual beliefs. Answers are rated on a 5-point Likert
scale (0 = not at all, 4 = very much). Item scores in each
scale are averaged to give scale scores; higher scores thus
represent greater wellbeing [27]. We used a Japanese ver-
sion of the FACIT-Sp, the reliability and validity of which
have been supported by Noguchi et al. [28].
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Clinical data at baseline and during follow-up
The following known clinical prognostic factors were
considered in the present study: age, sex, disease duration,
cirrhosis, diabetes mellitus, current and past consumption
of alcohol, alpha-fetoprotein (AFP), alanine transaminase
(ALT), platelet count, HCV genotype, sustained virological
response (SVR) and sustained biolochemical response
(SBR) to antiviral therapy (see Additional file 1 regarding
assessment of biochemical measurements). SVR was de-
fined as serum HCV RNA continuously negative for
>6 months after completion of interferon therapy. SBR was
defined as serum ALT decreased into the normal range
continuously for >6 months after termination of interferon
therapy. Liver cirrhosis was diagnosed using ultrasonog-
raphy (US), computed tomography (CT), or liver biopsy.
HCC was diagnosed based on typical findings on dynamic
CT or magnetic resonance imaging, and/or by histology.
Follow-up
Follow-up commenced on the date when the central of-
fice received signed consent form from the participant.
Information about the clinical course, such as occur-
rence of HCC, liver function, and treatment of CHC,
were collected by reviewing the participants’ medical
charts in September 2011. ALT as a marker of liver in-
jury was measured at each visit, with 1–3 month inter-
vals; however, one record per each follow-up year was
abstracted for the present analysis. If a participant did
not visit the hospital for more than six months, the
attending hepatologist contacted that participant to
obtain information about the participants’ medical
condition and reasons for the interruption. The hepa-
tologist also contacted the patient’s current attending
physician to obtain more detailed information, as ap-
propriate. Follow-up continued until the date of a
“disease progression,” until the last visiting date in
the case of participant dropout, or until 8 years of
continuous follow-up, whichever was earliest. Disease
progression was defined as either the first diagnosis
of HCC or hepatitis-related death, such as by hepatic
failure or upper gastro-intestinal bleeding.
Statistical analysis
Survival analysis using the Cox proportional hazards
model was applied to time-to-event data, where survival
was from the start-of-follow-up date to the end-of-follow-
up date, and the event was disease progression. Associ-
ation between each of the psychosocial factors and disease
progression was examined using a three-step multivariate
Cox regression analysis. Models in the first step included
a psychosocial variable of interest (continuous), and age
(continuous) and sex (male = 0, female = 1) as covariates.
Models in the second step were adjusted for age, sex,
baseline known risk factors (i.e. cirrhosis (dichotomous),
platelet count (≥ or <100,000/mm3), baseline ALT (< or
≥40 IU/L), AFP (< or ≥20 μg/L), diabetes (dichotomous),
current consumption of alcohol (dichotomous), and past
consumption of alcohol (dichotomous)), where platelet
count, baseline ALT, and AFP were averages of the three
latest measurements. Models in the third step included
these variables and treatment-related factors during the
follow-up period as covariates (i.e. ALT and response to
antiviral therapy). These treatment-related factors were set
as time-dependent variables, where ALT (< or ≥40 IU/L),
SVR (dichotomous), SBR (dichotomous), and no response
(dichotomous) was the latest value or status at every time-
point when an event occurred.
Baseline measurements of psychosocial variables may
have been affected by impaired physical conditions, es-
pecially for patients who were ill because of hepatitis-
related complications including latent HCC, which could
not have been represented by the baseline covariates
considered. Such an effect might have confounded the
association between psychosocial factors and disease
progression. To minimize the potential for such con-
founding, we repeated the above analyses after excluding
subjects for whom an event occurred in the first year of
follow-up (See previous reports that used similar
methods [29–31]). Reported P-values were two-sided;
SAS 9.4 was used for all statistical analyses.
Results
A consecutive series of 253 patients were assessed for
eligibility (see Fig. 1), of whom ten did not meet the
eligibility criteria: One was diagnosed with HCC and
four with other malignant diseases; four refused to
participate; and one had insufficient information for
enrollment. Three patients ceased visiting soon after
commencing participation and could not be contacted
any further. Data for the remaining 240 patients were
available for analysis, none of whom had a psychiatric
diagnosis or took any psychotropic agents regularly, ex-
cept for a short-acting sleep inducer. Table 1 summa-
rizes the participants’ baseline characteristics.
During the study period, 49 events occurred, including
46 newly diagnosed HCC and three hepatitis-related
deaths (two liver failures; one upper gastro-intestinal
bleeding). The remaining 191 were censored because of
hepatitis-unrelated death (N = 8: pancreas cancer, 2; lung
cancer, 1; breast cancer, 1; uterine corpus cancer, 1; bile
duct cancer, 1; cerebral bleeding, 1; unknown reason,
1); cessation of visiting (N = 69: reasons unrelated to
hepatitis, e.g. moving associated with job or family,
24; reasons possibly related to hepatitis, e.g. a complete
cure or remission of hepatitis or onset of cerebral bleed-
ing, 25; unknown reasons, 20); or the last visit by patients
who continued visiting until 30 September 2011 without
an event or death (N = 114). Median, range, and inter-
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quartile range of survival time were 7.5, 0.3–8.0, and 6.7–
7.7 years, respectively. A total of 146 patients (60.8 %) re-
ceived antiviral therapy (either IFN monotherapy or
combination therapy with pegylated IFN or IFN with
ribavirin) of whom 67, 33, and 46 exhibited SVR, SBR,
and no response to therapy at the end of follow-up, re-
spectively. Of the 146 patients, 25 had received antiviral
therapy before the start of follow-up, but did not receive
further antiviral therapy during the follow-up period.
The remaining 121 patients received 173 antiviral ther-
apies in total during the follow-up period: the number
of first, second, third, fourth, fifth, and sixth therapies were
90, 46, 24, 9, 3, and 1, respectively; and the number of SVR,
SBR, and no response were 66, 23, and 32, respectively.
Table 2 shows the association of known physical and
treatment-related risk factors and CHC progression,
after controlling for each other factor using multivariate
Cox regression models. In Model 1, which included age,
sex, and baseline status of known risk factors, only
cirrhosis and AFP were significantly and independently
associated with CHC progression. When treatment
related-factors during the follow-up period were add-
itionally entered as time-dependent variables (Model 2),
cirrhosis, AFP, and a recent high value of ALT were
significantly associated with subsequent disease progres-
sion. A model that only included the time-dependent
variables for antiviral therapy estimated the hazard ratios
(HRs) of SVR, SBR, and no response to be 0.91 (95 %
confidence interval, 0.35–2.32; P = 0.84), 1.68 (0.73–3.86;
P = 0.22), and 2.10 (1.07–4.12; P = 0.030), respectively, as
compared to no antiviral therapy (not shown in Table 2).
As shown in Table 2 (Model 2), however, none of the
treatment categories was significantly associated with
disease progression, after controlling for the baseline risk
factors and a recent high ALT value.
Table 3 shows the association between psychosocial
factors and the progression of CHC in the entire sample.
In age- and sex-adjusted models, higher scores on the SI
Type-I related scales, except for “low sense of control,”
were weakly associated with disease progression; how-
ever, none of these associations was statistically signifi-
cant. Additional adjustment for baseline known risk
factors did not change these associations, nor did further
adjustment for treatment-related factors. Regarding
QOL, in age- and sex-adjusted models, FACIT-G total
scores and scores on the FACIT-G subscales “physical
wellbeing,” “emotional wellbeing,” and “functional
Fig. 1 Flow diagram of participants
Table 1 Baseline characteristics of 240 patients with chronic
hepatitis C
Characteristic
Age, years 62.4 (9.1)a
Female 140 (58.3 %)
Duration, years 7.7 (5.1)a
HCV Genotype 1b 177 (73.8 %)
Anti-viral therapy 93 (38.8 %)
Cirrhosis 54 (22.5 %)
Diabetes 29 (12.1 %)
Current alcohol-drinker 66 (27.5 %)
Past alcohol-drinker 65 (27.1 %)
Aspartate aminotransferasec (IU/L) 40.0 [30.0–56.0]b
Alanine aminotransferasec (IU/L) 44.0 [32.0–59.0]b
Platelet count (×104/mm3) 14.8 [11.0–19.1]b
Albumin (g/dl) 4.2 [4.0–4.4]b
Bilirubin (mg/dl) 0.9 [0.7–1.1]b
Total cholesterol (mg/dl) 172 [153–197]b
Alpha fetoprotein (ng/ml) 5.5 [3.8–10.0]b
Readings are N (%) unless otherwise specified. aMean (standard deviation).
bMedian [inter-quartile range]. cMean of recent three measurements
Sawamoto et al. BioPsychoSocial Medicine  (2016) 10:24 Page 4 of 10
wellbeing,” FACIT-Sp total score, scores on the FACIT-Sp
“meaning/peace” subscale, and FACIT total score were
each significantly inversely associated with risk of disease
progression. All of these associations, however, were appre-
ciably attenuated to non-significant levels after additionally
controlling for baseline levels of known risk factors and
further controlling for treatment-related factors.
Table 4 shows associations between psychosocial
factors and disease progression in the subset of 227
participants in which seven participants diagnosed
with HCC and six censored in the first year of
follow-up were excluded from the participant set. In
age- and sex-adjusted models, associations with scores
on the type-I related scales were stronger in this sub-
set than in the complete participant group; however,
only the association with “unfulfilled need for accept-
ance” was statistically significant. These results were
similar after controlling for other factors. Age- and
sex-adjusted models also yielded stronger relation-
ships for scores on the FACIT scales in the subset
than among all participants, except for “social/family
wellbeing” (from the FACIT-G) and “faith” (from the
FACIT-Sp), which were not related to disease progres-
sion. Nonetheless, when the levels of known baseline
risk factors and/or treatment-related factors were add-
itionally controlled for, these associations generally
weakened to a non-significant level, with only the associ-
ation with “emotional wellbeing” consistently remaining
significant.
Discussion
To our knowledge, this is the first longitudinal study to
have examined the influence of psychosocial factors on
the disease progression of patients with CHC. A behav-
ioral pattern associated with the inhibition of emotional
needs and a subdomain of QOL representing emotional
wellbeing were found to be associated with the risk of
either an onset of HCC or hepatitis-related death, inde-
pendent of levels of known risk factors and treatment-
related factors.
The development of HCC and/or hepatitis-related
death are known to be predicted by the degree of fibrosis
and inflammation, represented by cirrhosis, low platelet
count, high AFP level, and high ALT level [32, 33]. As
serum transaminase levels fluctuate in patients with
CHC [34], a single measurement of ALT is insufficient
to predict disease progression [35]. Indeed, in the
present study, while the average of three recent mea-
surements of ALT at entry did not predict subsequent
events, a recent ALT level employed as a time-
dependent variable in the Cox model did. We also
attempted to introduce factors associated with antiviral
treatments into analysis, by using time-dependent vari-
ables representing the effects of recent antiviral therapy,
i.e. SVR, SBR, and no response. Other reported host fac-
tors include older age, male gender [32], overweight and
diabetes [33], and high alcohol consumption [34]. We
incorporated all of these known physical risk factors in
the analysis.
Table 2 Multivariate analysisa of demographic and known risk factors in association with subsequent disease progressionb in 240
patients with chronic hepatitis C
Model 1c Model 2d
Factor HR (95 % CI) P-value HR (95 % CI) P-value
Age, by 10 years 1.31 (0.88–1.96) 0.18 1.39 (0.93–2.09) 0.11
Female sex 1.10 (0.56–2.19) 0.78 1.28 (0.64–2.57) 0.48
Cirrhosis 4.23 (2.15–8.32) <0.001 4.36 (2.16–8.79) <0.001
Platelet count <100,000/mm3 1.41 (0.72–2.76) 0.31 1.57 (0.80–3.08) 0.19
Alanine aminotransferase >= 40 IU/l (baseline value) 1.02 (0.55–1.90) 0.94 0.84 (0.43–1.62) 0.60
Alpha fetoprotein >= 20 μg/l 2.50 (1.26–4.95) 0.009 2.35 (1.12–4.91) 0.023
Diabetes 1.17 (0.56–2.44) 0.68 1.14 (0.54–2.38) 0.73
Alcohol-drinking, currente 1.00 (0.42–2.41) 1.00 1.08 (0.45–2.60) 0.87
Alcohol-drinking, paste 1.56 (0.73–3.35) 0.25 1.42 (0.64–3.15) 0.39
Alanine aminotransferase >= 40 IU/l (recent value) f 2.21 (1.13–4.33) 0.021
Sustained virological response to antiviral therapyg 1.66 (0.60–4.60) 0.33
Sustained biological response to antiviral therapyg 0.94 (0.38–2.31) 0.89
No response to antiviral therapyg 1.17 (0.55–2.49) 0.68
HR hazard ratio, CI confidence interval. aUsing Cox proportional hazards models based on time-to-event data where event was defined as death associated with
hepatitis or diagnosis of HCC. bDisease progression was defined as either the first diagnosis of HCC or hepatitis-related death, such as hepatic failure and upper
gastro-intestinal bleeding. cDemographic and known risk factors for HCC at baseline. dDemographic and baseline risk factors, and treatment-related factors during
the follow-up period. eNo alcohol-drinking as reference. fTime-dependent variable, based on a latest measurement at every time-point when an event occurred.
gTime-dependent variable, no antiviral therapy as reference
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Causality is crucial in discussing the association be-
tween psychosocial factors and physical conditions.
Nagano et al. reported that a stronger tendency towards
type-I behavior is associated with severer CHC [8];
however, as their study was cross-sectional, it could not
exclude the possibility that psychosocial status was an
effect, rather than a cause, of the physical conditions. In
the present study, scores on both the SI type-I related
scales and the FACIT subscales were more clearly associ-
ated with disease progression when patients who en-
countered an event or were censored within the first
year of follow-up were excluded. This suggests that the
sample contained patients whose psychosocial status was
affected by impaired physical conditions, and that exclu-
sion uncovered the effect of psychosocial factors on
physical status. Further, while CHC severity’s association
with physical, functional, and social/familial wellbeing
was considerably attenuated by adjustment for baseline
levels of known physical factors, its association with
emotional wellbeing was not (see Table 4). Similarly,
CHC severity’s association with unfulfilled need for ac-
ceptance was unchanged by adjustment for physical
factors. This suggests that physical, functional, and
social/familial wellbeing were influenced by physical sta-
tus, and that the observed associations with disease pro-
gression were largely confounded by physical factors,
while those with emotional wellbeing and unfulfilled
need for acceptance were considerably independent of
physical factors.
“Unfilled need for acceptance” refers to a chronic un-
fulfilled need for others’ acceptance [8]. This construct
shares a common concept with repression of emotion,
relevant constructs of which are associated with the pro-
gression of HIV infection [36, 37] and the development
of malignant diseases [38, 39]. Additionally, unfilled
need for acceptance is related to a lack of social support,
which may also be important to the progression of HIV
infection [40] and malignant diseases [41, 42]. QOL rep-
resents patients’ experience or perception of their degree
of functioning in relation to illness, and reflects the ef-
fects of illness on multiple domains of patients’ health
and ability to perform activities of daily life [43]. Regard-
ing the subdomains of QOL assessed by the FACIT,
scores on emotional wellbeing were most consistently
Table 3 Psychosocial factors in association with subsequent disease progressiona in 240 patients with chronic hepatitis Cb
Model 1c Model 2d Model 3e
Scale HR (95 % CI) f P value HR (95 % CI) P value HR (95 % CI) P value
Stress Inventory
Type-I-related scales
Low sense of control 0.99 (0.78–1.25) 0.92 1.03 (0.80–1.32) 0.83 1.02 (0.79–1.32) 0.88
Object dependence of loss 1.15 (0.87–1.52) 0.32 1.16 (0.87–1.56) 0.31 1.18 (0.87–1.61) 0.28
Unfulfilled need for acceptance 1.19 (0.96–1.49) 0.12 1.17 (0.91–1.51) 0.23 1.18 (0.92–1.53) 0.20
Altruism 1.10 (0.85–1.42) 0.48 1.16 (0.87–1.56) 0.31 1.11 (0.83–1.48) 0.49
Total score 1.17 (0.86–1.59) 0.32 1.21 (0.85–1.70) 0.29 1.19 (0.84–1.69) 0.32
FACIT
FACIT-G
Physical wellbeing 0.56 (0.38–0.81) 0.002 0.84 (0.57–1.26) 0.41 0.90 (0.60–1.35) 0.60
Emotional wellbeing 0.64 (0.42–0.97) 0.036 0.73 (0.47–1.14) 0.16 0.73 (0.46–1.16) 0.19
Functional wellbeing 0.69 (0.52–0.91) 0.009 0.79 (0.56–1.13) 0.20 0.80 (0.56–1.13) 0.20
Social/familial wellbeing 1.14 (0.83–1.58) 0.41 1.02 (0.71–1.45) 0.93 0.91 (0.64–1.30) 0.61
Total score 0.55 (0.32–0.93) 0.025 0.69 (0.38–1.27) 0.24 0.67 (0.37–1.22) 0.19
FACIT-Sp
Meaning/peace 0.65 (0.45–0.94) 0.021 0.82 (0.56–1.21) 0.31 0.73 (0.49–1.08) 0.11
Faith 0.88 (0.65–1.19) 0.40 0.85 (0.60–1.19) 0.33 0.76 (0.53–1.07) 0.11
Total score 0.68 (0.46–0.99) 0.046 0.80 (0.53–1.20) 0.27 0.69 (0.46–1.05) 0.08
Total score (G + Sp) 0.54 (0.32–0.90) 0.019 0.68 (0.38–1.23) 0.21 0.62 (0.35–1.11) 0.11
HR hazard ratio, CI confidence interval, FACIT functional assessment of cancer therapy, FACIT-G FACIT-General, FACIT-Sp: FACIT-Spiritual
aDisease progression was defined as either the first diagnosis of HCC or hepatitis-related death, such as hepatic failure and upper gastro-intestinal bleeding. bUsing
Cox proportional hazards models fitted to time-to-event data where event was either death associated with hepatitis or diagnosis of hepatocellular carcinoma.
cAdjusted for age and sex. dAdjusted for age, sex, and baseline known risk factors; cirrhosis, alanine. eAdjusted for age, sex, baseline known risk factors, and
treatment-related factors during the follow-up period; ALT (most recent value) and results of antiviral treatments (sustained virological response, sustained biological
response, or no response) as time-dependent variables. fHR associated with a 1-point increment in the scores of the Stress Inventory scales and the FACIT scales
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associated with disease progression. By contrast, physical
wellbeing’s association with disease progression was at-
tenuated after controlling for physical factors, likely be-
cause this factor is more strongly affected by physical
illness than emotional wellbeing (see Additional file 2:
Table S2).
The mechanism underlying the relationship between
psychosocial factors and CHC prognosis is complex. Im-
proved wellbeing and behavioral patterns leading to
wellbeing may accompany a healthier lifestyle (e.g. low
alcohol consumption) [44]; however, they may also affect
the liver-brain axis, thus exerting anti-viral and anti-
carcinogenic effects on CHC via activation of the auto-
nomic nervous system. Additionally, chronic stress is
consistently associated with immune downregulation
[45]. For example, wellbeing is associated with increased
natural killer (NK) activity [46], while chronic psycho-
social stress is associated with reduced NK activity
[47–49]. The present data largely support these find-
ings, as scores on the type-I SI scales and the FACIT
scales were inversely and positively correlated with
NK activity, respectively (see Additional file 3: Table S1
and Additional file 2: Table S2). Furthermore, decreased
NK activity has been reported to be associated with ele-
vated risk of developing HCC in cirrhotic patients [50].
Nonetheless, association between psychosocial factors and
CHC prognosis in the present study did not change after
controlling for baseline alcohol consumption and NK ac-
tivity (cf. Table 3 and Additional file 4: Table S3; cf. Table 4
and Additional file 5: Table S4). This issue remains to be
clarified.
About 60 % of the patients received antiviral therapy
with IFN at least once by the end of follow-up. Because
the antiviral therapy, especially when it results in SVR, is
known to suppress the development of HCC [51, 52], we
considered this factor in the analysis. Patients may re-
ceive the therapy on more than one occasion and their
results can vary among SVR, SBR, and no response, so
we addressed this issue by introducing time-dependent
variables in the Cox proportional hazards model. In the
model including the baseline known risk factors and a
recent high value of ALT, SVR was not associated with
Table 4 Psychosocial factors in association with subsequent disease progressiona in 227 patients with chronic hepatitis C, after
excluding patients who met an event or was censored within the first one year of follow-upb
Model 1c Model 2d Model 3e
Scale HR (95 % CI) f P value HR (95 % CI) P value HR (95 % CI) P value
Stress Inventory
Type-I-related scales
Low sense of control 1.08 (0.84–1.40) 0.55 1.13 (0.85–1.49) 0.40 1.12 (0.84–1.48) 0.45
Object dependence of loss 1.21 (0.90–1.62) 0.20 1.23 (0.89–1.69) 0.21 1.25 (0.90–2.28) 0.11
Unfulfilled need for acceptance 1.31 (1.03–1.67) 0.026 1.33 (1.01–1.74) 0.041 1.35 (1.02–1.77) 0.036
Altruism 1.16 (0.88–1.53) 0.31 1.24 (0.90–1.70) 0.18 1.19 (0.87–1.63) 0.27
Total score 1.32 (0.94–1.83) 0.11 1.39 (0.96–2.02) 0.08 1.38 (0.95–2.01) 0.10
FACIT
FACIT-G
Physical wellbeing 0.53 (0.35–0.78) 0.002 0.76 (0.49–1.18) 0.22 0.80 (0.51–1.24) 0.32
Emotional wellbeing 0.54 (0.34–0.84) 0.006 0.60 (0.37–0.97) 0.036 0.60 (0.37–0.98) 0.041
Functional wellbeing 0.63 (0.47–0.85) 0.002 0.72 (0.49–1.04) 0.08 0.71 (0.49–1.04) 0.07
Social/familial wellbeing 1.11 (0.78–1.56) 0.57 1.00 (0.68–1.46) 1.00 0.91 (0.62–1.34) 0.63
Total score 0.45 (0.25–0.79) 0.006 0.56 (0.29–1.08) 0.08 0.54 (0.29–1.04) 0.07
FACIT-Sp
Meaning/peace 0.56 (0.38–0.83) 0.004 0.70 (0.46–1.07) 0.10 0.64 (0.41–0.98) 0.040
Faith 0.85 (0.61–1.18) 0.32 0.82 (0.57–1.18) 0.29 0.75 (0.52–1.10) 0.14
Total score 0.59 (0.39–0.90) 0.013 0.70 (0.45–1.09) 0.12 0.62 (0.40–0.98) 0.042
Total score (G + Sp) 0.43 (0.25–0.77) 0.004 0.55 (0.29–1.04) 0.06 0.51 (0.27–0.96) 0.037
HR hazard ratio, CI confidence interval, FACIT functional assessment of cancer therapy, FACIT-G FACIT-General, FACIT-Sp FACIT-Spiritual. aDisease progression was
defined as either the first diagnosis of HCC or hepatitis-related death, such as hepatic failure and upper gastro-intestinal bleeding.bUsing Cox proportional hazards
models fitted to time-event data where event was either death associated with hepatitis or diagnosis of hepatocellular carcinoma. cAdjusted for age and sex.
dAdjusted for age, sex, and baseline known risk factors; cirrhosis, alanine transaminase (ALT), platelet count, alpha fetoprotein, diabetes, and alcohol-drinking.
eAdjusted for age, sex, baseline known risk factors, and treatment-related factors during the follow-up period; ALT (most recent value) and results of antiviral
treatments (sustained virological response, sustained biological response, or no response) as time-dependent variables. fHR associated with a 1-point increment in
the scores of the Stress Inventory scales and the FACIT scales
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disease progression as compared to no therapy. This
may partly be explained by the fact that SVR occurred
relatively later in the follow-up period (e.g., 43 % oc-
curred 4 years or later from the start of follow-up).
Thus, latent HCCs that developed in a potentially high-
risk period preceding SVR may have become clinically
detectable after SVR. Moreover, another time-dependent
variable for a recent high value of ALT represents, at
least in part, consequences of antiviral therapies. The ad-
justment for this factor, together with the above men-
tioned “disadvantageous” condition for SVR, might have
masked the true effect of SVR in this particular cohort.
Another issue to be discussed about antiviral therapy is
IFN’s potential side effects on psychological status, in-
cluding induction or progression of depression [53, 54].
It is possible that the IFN therapy might change the psy-
chosocial status of some patients, and psychological and
behavioral aspects as evaluated via the SI and FACIT
scales might have been affected by antiviral therapy with
IFN. We cannot address this issue as we only assessed
the psychosocial factors at baseline, yet the observed as-
sociations with the psychosocial factors remained after
controlling for the antiviral therapies that the patients
received throughout the study period.
This study’s sample was small, which constitutes a
major limitation. Despite the long follow-up time, the
number of observed events was relatively small, and stat-
istical power may have been insufficient to detect all as-
sociations between psychosocial factors and disease
course. Although only the association with unfulfilled
need for acceptance was statistically significant, the dir-
ection of disease course’ associations with the other
type-I related scales of the SI seemed to be constant and
consistent with previous reports [8], and may have been
significant in a larger sample. Additionally, regarding the
FACIT subscales, in the baseline and treatment-related
factor adjusted models functional wellbeing and mean-
ing/peace were marginally significantly associated and
significantly associated with disease progression, respect-
ively. As recently reported [43, 55], subjectively assessed
functional wellbeing may be a prognostic factor for can-
cer patients, independent of objectively assessed per-
formance status, which is a known prognostic factor for
many malignant diseases [56, 57]. “Meaning/peace” rep-
resents an aspect of spirituality, a sense of meaning in
one’s life, inner harmony, peacefulness, and a sense of
comfort [58], and may be a critical resource for many
patients in coping with chronic and/or malignant dis-
eases [59]. Components of QOL such as functional well-
being and meaning/peace should also be studied in
larger samples. This study is also limited by the lack of
collected data permitting the discussion of the biological
mechanisms underlying the observed associations. We
obtained a single measurement of NK activity at
baseline; repeated measurements of NK activity or other
factors representing the neuro-endocrino-immunological
pathway would further advance understanding of the
mechanisms underlying the associations observed in this
study.
Conclusion
This study is the first report a possible effect of psycho-
social factors on the clinical course of patients with
CHC, based on an 8-year prospective analysis that took
into account known physical risk factors. Most possible
predictive factors include a behavioral pattern relevant
to the inhibition of emotional needs and a subdomain of
QOL relevant to emotional wellbeing; however, the con-
cept of type-I behavior and the other subdomains of
QOL also warrant further examination in a larger sam-
ple of CHC patients. Regarding clinical practice, it may
be more practical to address this topic if psychological
interventions aimed at improving the QOL of patients
with chronic diseases [60–62] are found to be able to re-
duce the risk of HCC and/or hepatitis-related death.
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